Interstitial nephritis secondary prevention: Difference between revisions
(Created page with "__NOTOC__ {{Interstitial nephritis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {...") |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | |||
'''Editor-In-Chief:''' [[User:C Michael Gibson|C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com <nowiki>[1]</nowiki>]; '''Associate Editor(s)-in-Chief:'''{{M.B}} | |||
== Overview == | |||
There are no established measures for the secondary prevention of [disease name]. | |||
OR | |||
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3]. | |||
== Secondary Prevention == | |||
The most important preventive action is to avoid exposure to the trigger of the acute episode. If the offending medication has clearly been identified, then avoiding future use of the medication is recommended, because AIN may recur on re-exposure to the original antigen. Where known cross-reactivity exists, for example between penicillins and cephalosporins, the risk of using a related agent should be carefully weighed against the benefit of using it. If such an agent is used, the patient should be appropriately monitored for any adverse effects. For the few patients who have chronic inflammatory diseases such as Sjogren syndrome, sarcoidosis, or SLE, adequate control of the underlying condition is important. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 05:48, 5 July 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:Mohsen Basiri M.D.
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
The most important preventive action is to avoid exposure to the trigger of the acute episode. If the offending medication has clearly been identified, then avoiding future use of the medication is recommended, because AIN may recur on re-exposure to the original antigen. Where known cross-reactivity exists, for example between penicillins and cephalosporins, the risk of using a related agent should be carefully weighed against the benefit of using it. If such an agent is used, the patient should be appropriately monitored for any adverse effects. For the few patients who have chronic inflammatory diseases such as Sjogren syndrome, sarcoidosis, or SLE, adequate control of the underlying condition is important.